Position in NVS
as of Jun 30, 2026
· filed Aug 3, 2026
Position Value
$45,988,386
+$8,311,836 QoQ
Shares Held
293,443
+19.0% QoQ
Ownership
0.015%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
#63
of 1,606 holders
Holding Since
Dec 2021
9 quarters on record
Voting authority
Sole 1%
Shared 99%
None 0%
Common Shares in NVS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026MASSACHUSETTS FINANCIAL SERVICES CO /MA/ holds $6,486,971,678 across 12 Drug Manufacturers - General names. NVS ranks #8 (0.7% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | JNJ |
Johnson & Johnson
|
10,539,098 | $2,676,614,716 | |
| 2 | PFE |
Pfizer Inc
|
56,551,011 | $1,361,748,341 | |
| 3 | ABBV |
AbbVie Inc.
|
4,388,338 | $1,104,281,370 | |
| 4 | GILD |
Gilead Sciences, Inc.
|
6,651,833 | $840,392,576 | |
| 5 | LLY |
ELI LILLY & Co
|
145,790 | $174,864,912 | |
| 6 | BIIB |
Biogen Inc.
|
744,892 | $160,941,363 | |
| 7 | BMY |
Bristol Myers Squibb Co
|
948,427 | $54,648,359 | |
| 8 | NVS |
Novartis AG
This page
|
293,443 | $45,988,386 |
All Filings in NVS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $45,988,386 | 293,443 | Shares | Defined | 2026-08-03 | |
| 2026-03-31 | $37,676,550 | 246,655 | Shares | Defined | 2026-05-14 | |
| 2025-12-31 | $15,680,919 | 113,737 | Shares | Sole | 2026-01-22 | |
| 2025-09-30 | $12,745,131 | 99,385 | Shares | Sole | 2025-10-29 | |
| 2025-06-30 | $9,013,791 | 74,488 | Shares | Sole | 2025-08-08 | |
| 2025-03-31 | $4,453,736 | 39,951 | Shares | Sole | 2025-05-02 | |
| 2024-12-31 | $1,924,012 | 19,772 | Shares | Sole | 2025-02-12 | |
| 2022-03-31 | $1,384,344 | 15,776 | Shares | Defined | 2022-05-11 | |
| 2021-12-31 | $1,274,700 | 14,573 | Shares | Defined | 2022-02-10 | |
| No filing history on record for this holder in this stock. | ||||||